http://dx.doi.org/10.5812/asjsm.42160.

Short-Acting Insulin Reduction Strategies for Continuous Cycle Ergometer Exercises in Patients with Type 1 Diabetes Mellitus

Othmar Moser,¹,²,³,* Gerhard Tschakert,² Alexander Mueller,²,⁴ Werner Groeschl,² Peter Hofmann,²

Thomas Pieber,¹ Jimmy Lawrence,⁵ and Gerd Koehler¹

¹Department of Internal Medicine, Medical University of Graz, Graz, Austria
²Institute of Sport Science, University of Graz, Graz, Austria
³Applied Sport, Technology, Exercise and Medicine Research Centre (ASTEM), Swansea University, Swansea, United Kingdom
⁴Sports Science Laboratory, FH JOANNEUM-University of Applied Sciences, Bad Gleichenberg, Austria
⁵Sociology of Physical Activity and Health, University of Potsdam, Potsdam, Germany

Corresponding author: Othmar Moser, A111 Engineering East, Fabian Way, Crymlyn Burrows, Swansea, SA1 8EN, United Kingdom. Tel: +44-1792511059, Fax: +44-31654396700, E-mail: othmar.moser@swansea.ac.uk

Received 2016 September 12; Revised 2016 November 08; Accepted 2016 December 12.

Abstract

Background: The fear of hypoglycemia is the strongest barrier when patients with type 1 diabetes mellitus consider physical activity. There is still a lack of information regarding pre- and post-exercise therapy adaptation strategies with different exercise intensities corresponding to the three phases of lactate metabolism.

Objectives: The aim of this experimental, cross-sectional study was to investigate exercise intensity-dependent, short-acting insulin reductions to avoid hypoglycemia, applying standardized exercises using insulin degludec (®Tresiba/Novo Nordisk, Denmark).

Methods: Seven male participants with type 1 diabetes mellitus were switched to insulin degludec. Intensities for the 30 minutes continuous cycle ergometer exercise tests were set at 5% below (A) and above (B) the lactate turn point 1, and below (C) and above (D) the lactate turn point 2. Reductions in short-acting insulin were applied as following: by 25% for intensity A, by 50% for intensity B and by 75% for intensities C and D four hours before the start of exercise and immediately after exercise. Blood glucose, interstitial glucose, lactate, catecholamines, cortisol, IGF-1 and glucagon were measured.

Results: No hypoglycemic events occurred, but linear blood glucose decreases were observed: 2.01 ± 1.04 mmol.L⁻¹, P = 0.35 (A), 3.00 ± 1.54 mmol.L⁻¹, P = 0.48 (B), 3.42 ± 2.34 mmol.L⁻¹, P = 0.40 (C), and 3.70 ± 3.36 mmol.L⁻¹, P = 0.12 (D). Adrenaline, noradrenaline and IGF-1 (B, C, D, not A), dopamine (C, D, not A and B) and cortisol (A, C, D, not B) increased significantly from baseline, but not glucagon (P > 0.05). Interstitial glucose showed no post-exercise hypoglycemia.

Conclusions: The applied therapy adaptation before and after exercises was adequate to avoid hypoglycemia while using an ultra-long-acting insulin.

Keywords: Glycemia, Metabolism, Hormones

1. Background

In addition to standard insulin therapy, regular exercise has been suggested to lead to positive effects in patients with diabetes by lowering the risk of cardiovascular diseases and early all-cause mortality (1). Furthermore, it was recently shown that adopting a healthy lifestyle in patients with type 1 diabetes mellitus led to an improvement in body fat, body mass index (BMI) and lipid profiles as well as in blood pressure (2). Despite this evidence, the fear of hypoglycemia is the strongest barrier when these patients consider physical activity (3). Exercise-induced hypoglycemia occurs if insulin levels are not adequately lowered before starting to exercise, resulting in an elevated risk of a high glucose uptake rate into the tissue (4). Three possible strategies have been identified to prevent exercise-induced hypoglycemia in patients with type 1 diabetes: first, insulin reduction (short-acting insulin (5-7) or insulin basal rate in pump therapy (8)), second, supplementation with carbohydrates (9) and third, the combination of insulin reduction and carbohydrate ingestion (10). As people with type 1 diabetes mellitus often suffer from weight gain (11), short-acting insulin reduction strategies arise as beneficial for weight management (12).

In the last few years, a novel ultra-long-acting insulin has been developed (insulin degludec (IDeg) (®Tresiba/ Novo Nordisk, Bagsvaerd, Denmark)). A recent study has shown that intensive insulin therapy with IDeg is related to less frequent nocturnal hypoglycemic events (13), lower levels and smaller day-to-day variability of fasting plasma glucose (14) while implementing a lower daily insulin dose (15). It also showed a comparable symptomatic and cognitive response to artificially induced hypoglycemia (16).
in comparison to insulin glargine (IGlar) (Lantus/ Sanofi-Aventis, France). Only a few studies have investigated physical exercise in patients with type 1 diabetes when treated with IDeg (17, 18). In a recent study (18), no hypoglycemic events were reported during 30 minutes cycle ergometer exercise at 65% peak oxygen uptake with either IDeg or IGlar, but this study only investigated one single exercise intensity. The incidence of late-onset hypoglycemia was similar for both basal insulins indicating a similar risk of hypoglycemia during and after exercise relative to other long-acting insulins. There are currently no recommendations to counteract exercise-induced hypoglycemia when using Ideg. Importantly, most studies investigating the effects of exercise in patients with type 1 diabetes mellitus prescribed exercise intensities as percentages of maximal oxygen uptake (\( \text{VO}_{2,\text{max}} \)) or maximal power output (\( P_{\text{max}} \)) (6, 19, 20), which results in inhomogeneous metabolic and cardiorespiratory responses as shown earlier (21, 22). IDeg has not yet proven to be effective in combination with different short-acting insulin reductions at exercise intensities near to or above the anaerobic threshold. There is a lack of information regarding pre- and post-exercise adaptation strategies for short-acting insulin with respect to different exercise intensities corresponding to the three phases of lactate metabolism. As a hypothesis we expected that standardized therapy adaptations are successful in avoiding hypoglycemia during and after exercise in patients with type 1 diabetes mellitus.

2. Objectives

The main aim of the present study was, therefore, to prove that standardized short-acting insulin dose reductions, dependent on specified exercise intensities, are successful in avoiding hypoglycemia during and after exercise. As a second aim, we assessed the acute metabolic, cardiopulmonary, and hormonal responses at these exercise intensities. A third aim was to extrapolate blood glucose decreases during continuous exercise at different exercise intensities to predict the maximal duration of exercise before hypoglycemia occurs.

3. Methods

3.1. Participants

To be eligible for the study, participants had to be male with type 1 diabetes mellitus for a duration of at least 12 months, aged 18 to 35 years, HbA\(_1c\) below 8 % (64 mmol/mol), fasting c-peptide below 0.3 nmol/L, treated with intensive insulin therapy, no disease-related long-term complications and no other physical and/or mental diseases. Just male participants were recruited since the female menstrual cycle influences glucose metabolism, and could interfere with the long investigation period. Participants were excluded if they had a history of any disease that could confound the results of the trial, use of drugs (which may interfere with the interpretation of the trial’s results or is known to be clinically relevant in interfering with insulin action), recovery from hypoglycemia, current alcohol addiction, controlled substance abuse (determined by investigator questioning, documented in the case report form (CRF)), known or suspected allergy to trial products or related products, language barriers precluding adequate understanding, unwillingness, mental incapacity, and any condition that the study physician feels would interfere with the trial participation. Testing day inclusion criteria were absence of hypoglycemia 48 hours prior to testing, documented by the participant by self-measured blood sugar and additionally controlled by the observation of the continuous glucose monitoring system (CGM) (Guardian, REAL-Time System, Medtronic, Fridley, Minnesota, USA) by the study physician, as well as no alcohol consumption 24 hours before testing determined by questioning (documented in the CRF). Testing day exclusion criteria were defined as: illness, glucose levels before testing below 4.4 mmol/L, CGM problems, incorrect time or amount of last short-acting insulin injection before testing. All inclusion and exclusion criteria were reported in a CRF. Hypoglycemia was set at \( \leq 3.9 \) mmol/L.

3.2. Measures

3.2.1. Preliminary Adjustment of Long-Acting Insulin Therapy

The usual long-acting insulin dose per day was determined by interviewing at the first visit four weeks prior to the study. IDeg (®Tresiba/Novo Nordisk, Bagsvaerd, Denmark) was subcutaneously injected once daily in the evening, starting with a dose of 70% of total daily long-acting insulin (16). In cases of hypo- or hyperglycemia, the insulin dose was adjusted. A run-in period of one month ensured an optimal long-acting insulin therapy.

3.3. Incremental Exercise Test

All participants performed an incremental cycle ergometer exercise test until exhaustion to determine exercise intensities for the subsequent continuous cycle ergometer exercise tests (21). At the beginning of the incremental exercise test, participants passively sat on the ergometer (3 min · 0 W). Afterwards participants warmed-up cycling for 3 minutes (40 W). Subsequently, the intensity was increased every minute (20 W) until maximal exhaustion, followed by 3 minutes active recovery (40 W) and 3 minutes passive recovery (0 W). The first (LTP\(_1\)) and
the second lactate turn point (LTP₂) were identified by a linear regression break point analysis (relationship of lactate concentration to power output). According to the three-phases of energy supply, LTP₁ and LTP₂ were determined as the intersection point between two regression lines. The individual test results were used to define the intensities for the continuous exercise tests for each patient. These workload intensities were set at 5% of Pmax below and above LTP, and LTP₂ do define four metabolically different individual exercise intensities. Exercise intensity below LTP₁ (A) conformed to regular physical activity as well as occupational work for several hours, and exercise above LTP₁ (B) conformed to moderate walking or low-intensity running. The intensity just below LTP₂ (C) matched to high-intensity continuous running or cycling in a metabolic steady state but for a limited duration, and the intensity above LTP₂ (D) corresponded to clearly limited exercise duration without a lactate steady state and with early termination due to exhaustion.

3.4. Continuous Cycle Ergometer Exercise Tests

Each patient performed four 30 minutes continuous cycle ergometer exercise tests (A, B, C, D). The four tests were separated by one week for recovery. Exercise intensities were not randomized in order to minimize potential risks, as the defined exercise intensities and short-acting insulin reductions were used for the first time in that experimental setting. Since only one exercise test of 30 minutes was performed within one week, no “training effects” were suggested, as no intra-individual differences were observed during passive and active warm-up periods in metabolic and cardiorespiratory responses. Tests began identically to the incremental exercise tests (passive and active warm-up) followed by a stepwise increase of exercise intensity (20 W.min⁻¹) until the final target workload for each subject was reached and maintained for 30 minutes. Finally, the cool-down period was similar to the incremental exercise test (3 minutes active recovery at 40 W and 3 minutes passive recovery at 0 W). The warm-up, the incremental approach to the target workload and the recovery phase were performed in order to control for day-to-day variability in physiological responses.

3.5. Analyses

Blood lactate and blood glucose concentrations were determined by taking capillary blood samples (ear lobe) during all tests at rest, warm-up, during exercise and recovery; blood samples were analyzed by means of a enzymatic-amperometric method (@Biosen S-line, EKF diagnostics, Germany). Breath-by-breath data were collected continuously during all tests, and 5 s average data were used for analyses (ZAN 600, ZAN, Germany). Heart rate was measured beat-to-beat during all tests, and 5 s average data were used for calculations (PE 4000, Polar Electro, Finland). A 12-lead electrocardiogram and blood pressure measurements (every 2 minutes) were used for cardiac monitoring. Venous samples of catecholamines, cortisol, insulin-like growth factor-1 (IGF-1), and glucagon were determined from a cubital vein before the start of the exercise, at 15 minutes during exercise, and at the end of each continuous 30 minutes exercise test (A - D). Adrenaline (limit of detection 10 pg.mL⁻¹), noradrenaline (limit of detection 50 pg.mL⁻¹), and dopamine (limit of detection 20 pg.mL⁻¹) were quantified by @RIA (DRG Diagnostics, USA). Glucagon (limit of detection 20 pg.mL⁻¹) was determined by @RIA (ICN, USA), and cortisol (detection of 0.20 - 75 µg.dL⁻¹) and IGF-1 (limit of detection 10.1 pg.mL⁻¹) by @CLIA (CENTAUR, siemens healthcare diagnostics, USA). C-peptide was measured by @Advia Centaur (CENTAUR, siemens healthcare diagnostics, USA) (detection of 0.05 - 30 ng.mL⁻¹).

3.6. Continuous Glucose Monitoring

Patients were fitted with a CGM and provided with all necessary instructions. The CGM sensor was inserted into the posterolateral abdominal region a minimum of 24 hours pre-exercise to measure blood glucose alongside self-measurement to avoid hypoglycemic events. The CGM was left inserted for another 24 hours post-exercise to observe glucose activity and the effect of exercise intensity (A, B, C, D). CGM alerts were set at below 4.4 mmol.L⁻¹ and above 16.0 mmol.L⁻¹ during the two 24 hours periods. The study physician asked about previous hypoglycemic events before the exercise tests, and any relevant information was documented in a CRF.

3.6.1. Short-Acting Insulin Reduction

After an overnight fast, each participant received a standardized meal (last meal before exercise testing) on test days (Fortimel Extra, Nutricia GmbH, Germany). The carbohydrate amount of 59 ± 8 g before to the tests was calculated on the mean amount at breakfast over the last four weeks prior the study. Standardized nutrition was composed of 39% carbohydrates, 36% proteins and 25% fat (Fortimel Extra, Nutricia GmbH, Germany). This standardized meal and the before mentioned short-acting insulin injections were administered four hours before the start of the exercise tests. This long time span was mainly applied to see the exercise-induced blood glucose decrease by minimizing the influence of short-acting insulin action during cycling. The short-acting insulin dose was reduced by 40% for the incremental exercise test, by 25% for exercise A, by 50% for exercise B and by 75% for both exercise intensities C and D, modified from Rabasa-Lhoret et al. (6). Post-exercise,
patients injected the same reduced short-acting insulin dose and ingested the same amount of carbohydrate as before testing to simulate post-exercise eating habits. For the rest of the day, patients were requested to continue with their regular insulin dose according to the formula (carbohydrate factor = (5.7 × bodyweight (kg)) / total daily insulin dose).

3.7. Procedures

All participants gave a signed informed consent prior to the trial started. The trial was approved by the local ethics committee, according to good clinical practice (GCP) and declaration of Helsinki (DoH) as well as approved by Clinicaltrials.gov. The study consisted of 20 visits at the outpatient clinic of Endocrinology and Metabolism, and at the exercise physiology laboratory. The outpatient clinic was visited for the adjustment to IDeg (visits 1 - 10, with three days in between) and to equip participants with CGM (visits 12, 14, 16, and 18, with one week in between). The exercise physiology laboratory was visited for the incremental exercise test (visit 11) and for the continuous cycle ergometer exercise tests (visits 13, 15, 17, and 19, with one week in between).

3.8. Statistical Analysis

A repeated-measures ANOVA design was calculated with an effect size of 0.5 and an α-error of 0.05 based on a pilot study with a main outcome defined as the expected blood glucose decrease. With a sample size of six patients with type 1 diabetes mellitus the power (β=1) is greater than 0.95. To control for dropout, we conducted our study with seven participants. Data were normally distributed except CGM levels, analyzed via Shapiro-Wilk normality test. Participants’ anthropometric data, performance characteristics and diabetes specific data are given as mean and range. Means of blood glucose decrease and hormone responses during exercise were calculated by repeated measures ANOVA and Tukey’s multiple comparison post-hoc test. Blood glucose decrease was extrapolated from the end of the test until reaching a hypoglycemic threshold of 3.9 mmol.L⁻¹. Relationships between blood glucose decreases and carbohydrate oxidation were performed by Pearson’s correlation coefficient analysis. CGM data are given as median and range (upper limit - lower limit), and coefficient of variation (CV) analysis from median was applied. For analysis of time spent in hyper- or hypoglycemia with the CGM we used the median and range for the values above 10.0 mmol.L⁻¹ or below 3.9 mmol.L⁻¹. All statistics were calculated with prism Software version 4.0 (GraphPad, USA).

4. Results

Seven men with type 1 diabetes mellitus were enrolled in this study (Table 1). All participants were switched to ultra-long-acting IDeg with an average dose of 68 ± 13% of their usual pre-study long-acting insulin dose, for daily conditions. All data were normally distributed.

Average oxygen consumption for each exercise intensity was 36 ± 10% VO₂max (A), 40 ± 13% VO₂max (B), 78 ± 11% VO₂max (C), and 84 ± 15% VO₂max (D). Blood lactate concentration profiles corresponded well to the expected patterns with resting lactate levels in A, slightly but significantly elevated steady state lactate levels in B, significantly elevated but still steady state lactate levels in C, but no steady state and a continuous increase of lactate with an early termination of exercise in D (Figure 1A).

The average short-acting insulin dose four hours before the exercise on each test day was 0.041 ± 0.014 U.kg⁻¹ for the incremental exercise test, 0.054 ± 0.014 U.kg⁻¹ for continuous cycle ergometer exercise A, 0.027 ± 0.014 U.kg⁻¹ for B, and 0.014 ± 0.007 U.kg⁻¹ for C and D, respectively. Those amounts were combined with a carbohydrate meal of 0.797 ± 0.069 g.kg⁻¹ (Fortimel Extra, Nutricia GmbH, Germany), which was the average amount ingested at breakfasts 4 weeks prior to the study start.

4.1. Blood Glucose Levels and Carbohydrate Oxidation

No participant experienced hypoglycemia (blood glucose ≤ 3.9 mmol.l⁻¹), neither during exercise nor within 24 hours after any of the 35 exercise sessions. All participants maintained a glucose steady state during the incremental exercise test when short-acting insulin was reduced by 40%, with no difference between the start and the end of the test (10.58 ± 3.42 mmol.L⁻¹ vs. (10.24 ± 3.48 mmol.L⁻¹, P = 0.85). Starting blood glucose for the continuous cycle ergometer exercise tests were found at 10.42 ± 2.01 mmol.L⁻¹ (range: 6.19 - 12.31 mmol.L⁻¹) for exercise intensity A, 12.78 ± 3.76 mmol.L⁻¹ (range: 7.44 - 16.01 mmol.L⁻¹) (B), 12.84 ± 3.21 mmol.L⁻¹ (range: 6.15 - 16.40 mmol.L⁻¹) (C), and 14.98 ± 2.43 mmol.L⁻¹ (range: 9.72 - 16.16 mmol.L⁻¹) (D) (Figure 2). Blood glucose linearly decreased in all continuous exercise sessions with delta values of 2.01 ± 1.04 mmol.L⁻¹, P = 0.35 (A), 3.00 ± 1.54 mmol.L⁻¹, P = 0.48 (B), 3.42 ± 2.34 mmol.L⁻¹, P = 0.40 (C), and 3.70 ± 3.36 mmol.L⁻¹, P = 0.12 (D), respectively. Delta blood glucose was not significantly different (P = 0.64) and not significantly correlated with carbohydrate oxidation (r = 0.31; P = 0.34). Carbohydrate oxidation, which was calculated from respiratory data, was 1.08 ± 0.39 g.min⁻¹ for A, 1.28 ± 0.42 g.min⁻¹ for B, 3.07 ± 0.44 g.min⁻¹ for C, and 4.02 ± 0.44 g.min⁻¹ for D (Figure 1B).
Table 1. Participants’ Characteristics, Performance Characteristics, and Diabetes Specific Data

<table>
<thead>
<tr>
<th>Variable</th>
<th>Characteristic</th>
<th>Characteristic</th>
<th>Characteristic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants’ characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24.7 (20 - 34)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height, m</td>
<td>1.76 (1.71 - 1.81)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>74 (66 - 81)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.9 (20 - 27)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VO₂max, ml/kg/m³.min⁻¹</td>
<td>P_{LT1}, W</td>
<td>P_{LT2}, W</td>
<td>P_{max}, W</td>
</tr>
<tr>
<td>52 (41 - 67)</td>
<td>82.1 (51 - 111)</td>
<td>192.1 (151 - 253)</td>
<td>284.3 (230 - 360)</td>
</tr>
<tr>
<td>Diabetes specific data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hba1c, %, mmol/mol</td>
<td>c-peptide, nmol/L⁻¹</td>
<td>Diabetes, y</td>
<td>CHO factor, g</td>
</tr>
<tr>
<td>7.4 (5.7 - 9.6)</td>
<td>0.13 (0.0 - 0.3)</td>
<td>16.9 (4 - 26)</td>
<td>12 (9 - 16)</td>
</tr>
</tbody>
</table>

Abbreviations: VO₂max, maximal oxygen uptake; P_{LT1}, Power at the first lactate turn point; P_{LT2}, Power at the second lactate turn point; P_{max}, maximal power output; CHO, carbohydrate.

*Value are expressed as Mean ± SD.

---

Figure 1. A: Lactate Concentrations During the 4 Continuous Exercise Tests (A, B, C, and D) Given as Mean ± SD. Solid Line for Exercise Intensity A, Broken Line for B, Dotted Line for C, and Dash-Dot Line for D. Differences in Lactate at Min Zero (Target Workload) Occur Due to Different Time Spans in the Warm-Up Period. B: Average Carbohydrate Oxidation Over Time (CHO) (g/min⁻¹) for the 4 Exercise Intensities (A, B, C, And D) Given as Mean ± SD. Significant Differences Were Found for All Tests (P < 0.01) Except a Vs. B (P = 0.36).

---

4.2. Late Glycemic Onset Measured by CGM

Median (range) glucose levels during 24 hours post exercise were 8.52 (4.99 - 12.30) mmol/L⁻¹ with a coefficient of variation (CV) of 16.49% (A), 9.86 (5.96 - 15.67) mmol/L⁻¹, CV 18.04% (B), 8.98 (5.91 - 13.57) mmol/L⁻¹, CV 24.90% (C), and 8.48 (5.57 - 13.36) mmol/L⁻¹, CV 28.15% (D). No hypoglycemia (≤ 3.9 mmol/L⁻¹) was found for all exercise intensities during the 24 hours post-exercise period. Hyperglycemic conditions (> 10.0 mmol/L⁻¹) were observed in A for 280 minutes with an average of 10.6 (10 - 12.1) mmol/L⁻¹, in B for 660 minutes with 10.9 (10 - 14.5) mmol/L⁻¹, in C for 415 minutes with 11.5 (10 - 14.7) mmol/L⁻¹, and in D for 340 minutes with 11.8 (10 - 15.9) mmol/L⁻¹ (Figure 3).

4.3. Hormone Levels

Adrenaline (C and D, P < 0.01), noradrenaline (B, C and D, P < 0.01), dopamine (C and D, P < 0.01), cortisol (A, P = 0.03; C, P = 0.01 and D, P = 0.03), and IGF-1 (B, P = 0.04; C and D, P < 0.01) but not glucagon (P > 0.05) significantly increased during constant load exercise (Figure 4). The time course of adrenaline, noradrenaline, and cortisol was similar to the pattern of blood lactate concentrations. This clearly displayed the expected three phase time course for these variables with no increase for intensities A and B, but...
a significant increase in C, and a marked elevation and no steady state in D.

5. Discussion

Our study included low and high exercise intensities at 5% of $P_{\text{max}}$ below and above both lactate turn points. Even for high intensity exercise (C and D), the applied short-acting insulin reductions in combination with IDeg were found to be safe. This is highly relevant since many patients with type 1 diabetes mellitus are performing high-intensity competitive sports (23). In comparison to the findings of Heise and colleagues (18), where exercise intensity was set at 65% of $V_{\text{O2max}}$ with the same duration as in our study (30 minutes), the observed blood glucose decrease was higher in our study. Due to different exercise prescription methods and differences in exercise intensities, a comparison of these results is difficult. Our study showed a dose-response relationship of exercise intensity and the decrease of blood glucose concentration during continuous cycle ergometer exercises independent of insulin reduction. The blood glucose decrease was linear with time and was dependent on exercise intensity, which allows to estimate critical time limits (time to reach the hypoglycemic threshold of 3.9 mmol.L$^{-1}$) as well as to prospectively calculate the risk of hypoglycemia. The linear extrapolation of the blood glucose decrease during exercises A, B, C, and D showed an intensity-related range of duration between 120 ± 56 minutes (A) and 59 ± 52 minutes (D) to reach the hypoglycemic threshold. A prospective calculation of the expected blood glucose decrease might be a simple method which could be used easily by the patients themselves, and which could help patients learn when and how to supplement carbohydrates with respect to exercise intensity and duration. For conclusive recommendations, however, additional large-scale studies are required specifically on the influence of the pre-exercise glucose concentration. Since we started at high blood glucose levels in our tests, it has to be critically mentioned that these conditions (although usual in daily practice) (23) might influence the glucose consump-
As we just used the recommended intensity-dependent insulin reduction strategy with standardized exercise conditions, further studies are necessary to investigate different reduction strategies for short-acting insulin related to our theoretical exercise prescription model, including a greater number of subjects. Despite these limitations, our study was able to show that individual recommendations for the reduction of short-term insulin are possible.
and safe if applied to individually defined exercise intensities. The method of our study allows to identify the individual exercise intensity-dependent, maximal duration, before reaching the hypoglycaemia threshold during a constant load exercise with a given insulin reduction strategy, instead of an overall recommendation.

Figure 4. Comparison of Adrenaline (A), Noradrenaline (B), Dopamine (C), Cortisol (D), Glucagon, (E) and IGF-1 (F) With Respect to the Four Different Exercise Intensities, Given as Mean ± SD. Solid Line For Exercise Intensity A, Broken Line For B, Dotted Line for C, and Dash-Dot Line For D
Footnotes

Authors’ Contribution: Othmar Moser was responsible for the study concept and design, acquisition of data, analysis and interpretation of data, drafting the manuscript, statistical analysis, and study supervision. Gerhard Tschakert contributed to the analysis and interpretation of data, drafting the manuscript and statistical analyses. Alexander Mueller contributed to the acquisition of data, administrative, technical, and material support. Werner Groeschl contributed to the acquisition of data and analysis and interpretation of data. Peter Hofmann was responsible for the study concept and design, analysis and interpretation of data, critical revision of the manuscript for important intellectual content. Thomas Pieber and Jimmy Lawrence were contributed to the critical revision of the manuscript for important intellectual content and statistical analysis. Gerd Koehler was responsible for concept and design, acquisition of data, analysis and interpretation of data, drafting the manuscript, statistical analysis, and study supervision.

Conflict of Interest: No conflict of interest for Othmar Moser, Gerhard Tschakert, Alexander Mueller, Werner Groeschl, Jimmy Lawrence and Peter Hofmann. Thomas Pieber has participated in advisory panels and acted as a consultant for Novo Nordisk. Gerd Koehler has received lecture fees from Novo Nordisk, AstraZeneca, Bristol-Myers Squibb, Roche Diagnostics, Novartis, MSD and Eli Lilly.

Funding/Support: This study was self-funded.

References


